Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tumor neoantigenicity metric improves prediction of response to immunotherapy

Key clinical point: Compared with existing metrics, the Cauchy-Schwarz index of neoantigens (CSiN) score may be better at predicting response to immunotherapy among patients with immunogenic cancer.

Major finding: There was a significant positive association between higher CSiN scores and better response among melanoma patients who received anti–CTLA-4 therapy (P = .009), patients with clear cell renal cell carcinoma treated with anti-PD-1/PD-L1 therapy (P = .036), and patients with non–small cell lung cancer treated with checkpoint inhibitors (P = .015).

Study details: A retrospective study of 2,479 cancer patients.

Disclosures: The study was funded by the National Institutes of Health, the Cancer Prevention Research Institute of Texas, and the American Cancer Society. The investigators reported no conflicts of interest.

Citation:

Lu et al. Sci Immunol. 2020 Feb 21. doi: 10.1126/sciimmunol.aaz3199.